Lancet Publishes COURAGE: Regeneron's Trevogrumab Preserved Lean Mass on Semaglutide, but the Garetosmab Combination Had High Dropout
In the Phase 2 COURAGE trial of 975 adults with obesity at 60 U.S. sites, people on semaglutide plus placebo lost 6.6% of their lean mass by week 26; adding trevogrumab 200 mg, an antibody against myostatin (GDF8), reduced that loss by 3.1 percentage points, and adding trevogrumab 400 mg with garetosmab reduced it by 4.5 points. In part B, trevogrumab 75 mg reduced 52-week lean-mass loss by 3.1 points vs. 7.3% on semaglutide plus placebo, while 25 mg did not differ significantly. The garetosmab combination had serious adverse events in 9% of participants, 32% discontinued treatment, 41% had muscle spasms, and both deaths in the trial occurred in that group, though investigators did not find a causal link, The Lancet paper reports.